Cellares

South San Francisco, CA
Find alternatives to Cellares for CAR-T →
Platform Provider
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP

Quick Facts: Cellares

Signal Score
59.0/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
South San Francisco, CA
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Cellares

Industry 4.0 IDMO model. Cell Shuttle.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: South San Francisco, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: South San Francisco, CA
Press Signals20 articles (not scored)
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

Hiring Activity 1 open role Beta

From public job postings on Cellares' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
1
open role
1
in manufacturing, quality, PD/MSAT, engineering or regulatory (100%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
Engineering & facilities 1
By site
South San Francisco, CA profile site
· 1 eng.
1
Latest postings
Senior Automation Engineer Engineering & facilities · South San Francisco, CA · posted Oct 6, 2026
Coverage: counted from Cellares' own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: jobs.lever.co · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-05
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply  MyChesCo
general 2026-05-01
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal - megaproject.com
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal  megaproject.com
general 2026-04-29
Cellares to manufacture Cabaletta CAR-T under 10-year deal - NJBIZ
Cellares to manufacture Cabaletta CAR-T under 10-year deal  NJBIZ
general 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
Cabaletta Bio signs 10-year manufacturing deal with Cellares  Investing.com
general 2026-04-28
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel  Business Wire
general 2026-04-28
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel  The Manila Times
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Canada
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com Canada
general 2026-04-28
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel  BioSpace
general 2026-04-28
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy  Contract Pharma
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com UK
general 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com UK
Cabaletta Bio signs 10-year manufacturing deal with Cellares  Investing.com UK
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com
regulatory 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com  Investing.com India
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Australia
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com Australia
regulatory 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com  Investing.com India
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com UK
general 2026-04-15
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy - The National Law Review
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy  The National Law Review
general 2026-04-14
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - Business Wire
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform  Business Wire
general 2026-04-14
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients - Genetic Engineering and Biotechnology News
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients  Genetic Engineering and Biotechnology News
general 2026-04-14
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform  National Today

Frequently Asked Questions About Cellares

What is Cellares's CDMO Signal Score?
Cellares has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cellares for a manufacturing program?
Use the free AI matchmaker to compare Cellares against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy

Compare Cellares with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Cellares
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.